Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study

BACKGROUND: The bromodomain and extraterminal protein (BET) inhibitor trotabresib has demonstrated antitumor activity in patients with advanced solid tumors, including high-grade gliomas. CC-90010-GBM-001 (NCT04047303) is a phase I study investigating the pharmacokinetics, pharmacodynamics, and CNS...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, Victor, Manuel Sepúlveda, Juan, Reardon, David A, Pérez-Núñez, Ángel, González León, Pedro, Hanna, Bishoy, Filvaroff, Ellen, Aronchik, Ida, Chang, Henry, Amoroso, Barbara, Zuraek, Marlene, Sanchez-Perez, Tania, Mendez, Cristina, Stephens, Daniel, Nikolova, Zariana, Vogelbaum, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237409/
https://www.ncbi.nlm.nih.gov/pubmed/36455228
http://dx.doi.org/10.1093/neuonc/noac263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237409/
https://www.ncbi.nlm.nih.gov/pubmed/36455228
http://dx.doi.org/10.1093/neuonc/noac263

Ejemplares similares